Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in
combination with tuvusertib (M1774) in treating patients with solid tumors that have spread
to other places in the body (advanced). Peposertib and tuvusertib cells by blocking some of
the enzymes needed for cell growth.